StockNews.com Begins Coverage on Minerva Neurosciences (NASDAQ:NERV)

StockNews.com initiated coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a research report sent to investors on Tuesday. The firm issued a sell rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright restated a “neutral” rating and issued a $5.00 target price on shares of Minerva Neurosciences in a report on Wednesday, November 6th.

Minerva Neurosciences Stock Performance

Minerva Neurosciences stock opened at $2.26 on Tuesday. Minerva Neurosciences has a 1 year low of $2.07 and a 1 year high of $13.49. The firm has a 50 day moving average price of $2.46 and a 200 day moving average price of $2.77. The company has a market cap of $15.77 million, a price-to-earnings ratio of -5.13 and a beta of 0.18.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.